Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines

Molecular Carcinogenesis

Volumn 53, Issue 3, 2014, Pages 230-242

  Beierle, Elizabeth A ^a   Ma, Xiaojie ^b   Stewart, Jerry E ^a   Megison, Michael ^a   Cance, William G ^c   Kurenova, Elena V ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

AV3; FLT 4; Neuroblastoma; Pediatric; PTK 2

Indexed keywords

AV3; FLT-4; NEUROBLASTOMA; PEDIATRIC; PTK-2;

APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; FOCAL ADHESION KINASE 1; HUMANS; IMMUNOPRECIPITATION; NEUROBLASTOMA; PHOSPHORYLATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84894241649     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21969     Document Type: Article

References (58)

1. Cotterill S, Parker L, More L, Craft A. Neuroblastoma: Changing incidence and survival in young people aged 0-24 years. A report from the North of England Young Persons' Malignant Disease Registry. Med Pediatr Oncol 2001; 36:231-234.
2. Hanks S, Polte T. Signaling through focal adhesion kinase. Bioessays 1997; 19:137-145.
3. Zachary I. Focal adhesion kinase. Int J Biochem Cell Biol 1997; 29:929-934.
4. Gabarra-Niecko V, Schaller M, Dunty J. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 2003; 22:359-374.
5. Schaller M, Borgman C, Cobb B, Vines R, Reynolds A, Parsons J. pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA 1992; 89:5192-5196.
6. Xu L, Yang X, Bradham C, et al. The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells. Involvement of death receptor-related signaling pathways. J Biol Chem 2000; 275:30597-30604.
7. Xu L, Yang X, Craven R, Cance W. The COOH-terminal domain of the focal adhesion kinase induces loss of adhesion and cell death in human tumor cells. Cell Growth Differ 1998; 9:999-1005.
8. Xu L, Owens L, Sturge G, et al. Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells. Cell Growth Differ 1996; 7:413-418.
9. Golubovskaya V, Beviglia L, Xu L, Earp Hr, Craven R, Cance W. Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem 2002; 277:38978-38987.
10. Han E, Mcgonigal T, Wang J, Giranda V, Luo Y. Functional analysis of focal adhesion kinase (FAK) reduction by small inhibitory RNAs. Anticancer Res 2004; 24:3899-3905.
11. Lipinski C, Tran N, Menashi E, et al. The tyrosine kinase pyk2 promotes migration and invasion of glioma cells. Neoplasia 2005; 7:435-445.
12. Ryu S, Cho K, Oh Y, Park S. Role of Src-specific phosphorylation site on focal adhesion kinase for senescence-associated apoptosis resistance. Apoptosis 2006; 11:303-313.
13. Halder J, Landen CJ, Lutgendorf S, et al. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res 2005; 11:8829-8836.
14. Beierle E, Massoll N, Hartwich J, et al. Focal adhesion kinase expression in human neuroblastoma: Immunohistochemical and real-time PCR analyses. Clin Cancer Res 2008; 14:3299-3305.
15. Beierle E, Trujillo A, Nagaram A, et al. N-MYC regulates focal adhesion kinase expression in human neuroblastoma. J Biol Chem 2007; 282:12503-12516.
16. Beierle EA, Trujillo A, Nagaram A, Golubovskaya VM, Cance WG, Kurenova EV. TAE226 inhibits human neuroblastoma cell survival. Cancer Invest 2008; 26:145-151.
17. Beierle E, Ma X, Stewart J, et al. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle 2010; 9:1005-1015.
18. Jussila L, Valtola R, Partanen T, et al. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res 1998; 58:1599-1604.
19. Dumont D, Jussila L, Taipale J, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998; 282:946-949.
20. Liu X, Sun X, Wu J. Expression and significance of VEGF-C and FLT-4 in gastric cancer. World J Gastroenterol 2004; 10:352-355.
21. van Iterson V, Leidenius M, von Smitten K, Bono P, Heikkilä P. VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasive lobular breast cancer. Am J Clin Pathol 2007; 128:759-766.
22. Saintigny P, Kambouchner M, Ly M, et al. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: Concurrent expression in cancer cells from primary tumour and metastatic lymph node. Lung Cancer 2007; 58:205-213.
23. Herrmann E, Eltze E, Bierer S, et al. VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: Relationships to clinicopathological parameters and long-term survival. Anticancer Res 2007; 27:3127-3133.
24. Jennbacken K, Vallbo C, Wang W, Damber J. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 2005; 65:110-116.
25. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454:656-660.
26. Laakkonen P, Waltari M, Holopainen T, et al. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res 2007; 67:593-599.
27. Beierle E, Dai W, Langham MJ, Copeland ER, Chen M. VEGF receptors are differentially expressed by neuroblastoma cells in culture. J Pediatr Surg 2003; 38:514-521.
28. Beierle E, Dai W, Langham MJ, Copeland E, Chen M. Expression of VEGF receptors in cocultured neuroblastoma cells. J Surg Res 2004; 119:56-65.
29. Lagodny J, Jüttner E, Kayser G, Niemeyer C, Rössler J. Lymphangiogenesis and its regulation in human neuroblastoma. Biochem Biophys Res Commun 2007; 352:571-577.
30. Rössler J, Taylor M, Geoerger B, et al. Angiogenesis as a target in neuroblastoma. Eur J Cancer 2008; 44:1645-1656.
31. Kurenova E, Hunt D, He D, Magis A, Ostrov D, Cance W. Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. J Med Chem 2009; 52:4716-4724.
32. Garces C, Kurenova E, Golubovskaya V, Cance W. Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells. Cancer Res 2006; 66:1446-1454.
33. Beierle E, Ma X, Trujillo A, Kurenova E, Cance W, Golubovskaya V. Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines. Mol Carcinog 2010; 49:224-234.
34. Kurenova E, Xu L, Yang X, et al. Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein. Mol Cell Biol 2004; 24:4361-4371.
35. Nowicki M, Konwerska A, Ostalska-Nowicka D, et al. Vascular endothelial growth factor (VEGF)-C-A potent risk factor in children diagnosed with stadium 4 neuroblastoma. Folia Histochem Cytobiol 2008; 46:493-499.
36. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur G, Himelstein B. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 2000; 6:1900-1908.
37. Uçar K, Seeger R, Challita P, et al. Sustained cytokine production and immunophenotypic changes in human neuroblastoma cell lines transduced with a human gamma interferon vector. Cancer Gene Ther 1995; 2:171-181.
38. Nguyen T, Hocker JE, Thomas W, et al. Combined RAR alpha- and RXR-specific ligands overcome N-myc-associated retinoid resistance in neuroblastoma cells. Biochem Biophys Res Commun 2003; 302:462-468.
39. Joukov V, Kumar V, Sorsa T, et al. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem 1998; 273:6599-6602.
40. Komuro H, Kaneko S, Kaneko M, Nakanishi Y. Expression of angiogenic factors and tumor progression in human neuroblastoma. J Cancer Res Clin Oncol 2001; 127:739-743.
41. Sallinen H, Anttila M, Narvainen J, et al. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol Ther 2009; 17:278-284.
42. Burton J, Priceman S, Sung J, et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res 2008; 68:7828-7837.
43. Heckman C, Holopainen T, Wirzenius M, et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res 2008; 68:4754-4762.
44. Kurenova E, Hunt D, He D, et al. Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo. Cell Cycle 2009; 8:2266-2280.
45. Manders EMM, Verbeek FJ, Aten JA. Measurement of colocalization of objects in dual-color confocal images. J Microsc 1993; 169:375-382.
46. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer. Clin Cancer Res 2003; 9:5313-5317.
47. Zeng Y, Opeskin K, Baldwin M, et al. Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res 2004; 10:5137-5144.
48. Mehnert J, McCarthy M, Jilaveanu L, et al. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol 2010; 41:375-384.
49. Onogawa S, Kitadai Y, Tanaka S, Kuwai T, Kimura S, Chayama K. Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci 2004; 95:32-39.
50. Lui Z, Ma Q, Wang X, Zhang Y. Inhibiting tumor growth of colorectal cancer by blocking the expression of vascular endothelial growth factor receptor 3 using interference vector-based RNA interference. Int J Mol Med 2010; 25:59-64.
51. Masood R, Kundra A, Zhu S, et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 2003; 104:603-610.
52. Matsuura M, Onimaru M, Yonemitsu Y, et al. Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells. Am J Pathol 2009; 175:1709-1721.
53. Chen HC, Guan JL. The association of focal adhesion kinase with a 200-kDa protein that is tyrosine phosphorylated in response to platelet-derived growth factor. Eur J Biochem 1996; 235:495-500.
54. Sieg DJ, Hauck CR, Ilic D, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000; 2:249-256.
55. Liu W, Bloom D, Cance W, Kurenova E, Golubovskaya V, Hochwald S. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 2008; 29:1096-1107.
56. Kirkin V, Baumann P, Mazitschek R, et al. MAZ51, an indoline that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. Int J Cancer 2004; 112:986-993.
57. Weinstein IB. Cancer. Addiction to oncogenes-The Achilles heal of cancer. Science 2002; 297:63-64.
58. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008; 68:3077-3080.